|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Re: trabalhos interessantes IXFrom: Joao Lindolfo Cunha Borges, MD, CCD (jlborges@metabolismo.com.br)Tue, 27 Mar 2001 03:43:41 -0300
Caro Jaime Ipriflavona não aumenta massa óssea e nem diminui o risco de fraturas. Todos trabalhos com esta substância foram realizados por um tempo muito curto e número limitado de voluntários. No último congresso mundial de osteoporose, foi mostrado um trial razoavelmente bem feito que mostrou a inutilidade desta medicação. Ipriflavona é vendida no Japão, alguns países da Europa e em países do terceiro mundo. Olha o que diz uma revisãoapresentada no congresso de osteoporose: "Ipriflavone Ipriflavone is a flavonoid derivative with moderate simil-estrogenic activity on bone tissue but with apparently no effect on other typical target organs for estradiol. It is marketed in Japan and in a few European countries for prevention and treatment of osteoporosis. This indication comes from a few small-sized studies demonstrating some effect on bone mass.[15-17] Its mechanism of action and efficacy continue to be investigated.[18-20]" Em suma, um "ouro de tolo" comercializado e prescrito no Brasil sem qualquer suporte científico. Abraços Joao Lindolfo C. Borges, MD, CCD
>----- Original Message -----
> -- > -------------------------------------------------------------------------- > ---- > -------------------------------------------------------------------------- > > WESTPORT, CT (Reuters Health) Mar 20 - Ipriflavone therapy does not inhibit > bone resorption or increase bone formation in postmenopausal women, > according to members of the Ipriflavone Multicenter European Fracture Study > Group. However, this synthetic isoflavone derivative, sold over the counter > in many countries, does induce lymphocytopenia in a significant proportion > of users. > > Dr. Peter Alexandersen, of the Center for Clinical and Basic Research in > Ballerup, Denmark, and associates prospectively compared the outcomes of 234 > postmenopausal women randomly assigned to receive ipriflavone 200 mg t.i.d. > and 240 who were assigned to placebo. All subjects also received 500 mg/day > of calcium. Results based on intent-to-treat analysis are reported in The > Journal of the American Medical Association for March 21. > > Bone mineral density at the lumbar spine, hip, and distal radius were not > significantly different from baseline after 36 months of treatment, the > researchers found. Biochemical markers of bone turnover — serum alkaline > phosphatase, fasting urinary hydroxyproline corrected by creatinine, serum > calcium, serum phosphorus, and urinary excretion of calcium corrected for > creatinine — were likewise similar between groups. > > The concentration of circulating lymphocytes decreased significantly below > 500/mcL in 13.2% of subjects treated with ipriflavone. Approximately half of > these recovered to normal values within 12 months, but after 24 months, 19% > remained lymphocytopenic. > > "The relative benefit-risk ratio of ipriflavone appears low when compared > with the alternative antiosteoporotic drugs available," Dr. Alexandersen's > team concludes. > > JAMA 2001;285:1482-1488. > > Jaime Nonato http://www.geocities.com/jjndo jaimen@zaz.com.br >
Voltar para Administrador da lista: flavio.monteiro.desouza@obgyn.net Solicitações à lista: obstet-l-request@obgyn.net Última atualização: Mon May 19 16:34:10 2008 |
|
